Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988635 | 0.88 | BTK (0.52) | BTKKDM4ETGM2CYP19A1LMNA | |
| SCHEMBL9568733 | 0.81 | BTK (0.63) | BTKKDM4ECA1CA2PIK3CD | |
| SCHEMBL9568677 | 0.80 | TGM2 (0.58) | BTKTGM2 | |
| SCHEMBL23988608 | 0.80 | EPHB4 (0.47) | BTKKDM4ECA2PIK3CDPIK3C2G | |
| SCHEMBL20885071 | 0.78 | LMNA (0.51) | KDM4ECA1CA2TGM2LMNA | |
| SCHEMBL23988636 | 0.77 | EGFR (0.49) | BTKPIK3CDPIK3C2GPIK3CGTGM2 | |
| SCHEMBL9568667 | 0.76 | TGM2 (0.55) | BTKTGM2LMNA | |
| SCHEMBL23988634 | 0.75 | TGM2 (0.58) | KDM4ECA1CA2TGM2LMNA | |
| SCHEMBL9568629 | 0.73 | TGM2 (0.58) | BTKKDM4ETGM2SMN1; SMN2 | |
| SCHEMBL9568796 | 0.72 | TGM2 (0.58) | TGM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | BTK 58/4885KDM4E 2713/4885CA1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.